How it Works

No pain, no drugs, no needles, no withdrawals - just the science of light!

Laser light therapy for smoking cessation is used to balance the energy flow in the body, which promotes the release of endorphins - a natural chemical produced by the body.

Laser light is applied to energy points related to addiction. The procedure is external, non-invasive and drug free. During the treatment laser light is applied to points on your hands, face and ears. Clients may feel a warm pulsating or a tingling feeling. The initial treatment consists of two 30 minute sessions 24 hours apart and a third session to be taken at the discretion of the client.

The treatment is effective in 'leveling out' a smokers endorphin levels, which can spike abnormally high whilst smoking and crash to abnormal low levels soon after smoking, thus eliminating the constant cravings associated with quitting. Light therapy has been clinically proven to be up 9 times more effective than nicotine patches in the cessation of smoking.

It really is that simple. After one hour you could be a non smoker with all the benefits associated with that.

Live longer, live healthier with FREEDOM Laser Therapy.

Bonus*

Every time you smoke you damage your skin. When you quit you stop the damage caused by smoking and avoid the premature aging that goes along with it. Quit now and discover the numerous benefits of healthier skin.

INCREASE COLLAGEN
DECREASE TOXINS
INCREASE VITAMIN ABSORPTION
REPLENISH OXYGEN
LIMIT SMOKER LINES

 

Does it work?

In clinical studies

Multiple double-blinded clinical studies have proven a high level of effectiveness for this laser treatment. In one such study at the Middlesex University of 340 patients, 70% of those treated with the laser stopped smoking. Clinical results show that Laser Therapy Treatments are up to 9 times more effective than nicotine patches in helping patients quit smoking.*

* Low Level Laser Therapy - Double blind study to assess the efficacy of L.L.L.T. as a treatment for stopping smoking"
Middlesex University clinical trial 2002, Paul Lowe, Katherine Kerr